Analysis of HIF-1 inhibition by manassantin A and analogues with modified tetrahydrofuran configurations

doi:10.1016/j.bmcl.2009.04.071

Bioorganic & Medicinal Chemistry Letters

Volume 19, Issue 14, 15 July 2009, Pages 3783-3786

https://doi.org/10.1016/j.bmcl.2009.04.071 Get rights and content

Abstract

We have shown that manassantin A downregulated the HIF-1α expression and inhibited the secretion of VEGF. We have also demonstrated that the 2,3-cis-3,4-trans-4,5-cis-configuration of the tetrahydrofuran is critical to the HIF-1 inhibition of manassantin A.

Graphical abstract

HIF-1 inhibition by manassantin A (1) and analogues with modified tetrahydrofuran configurations (11 and 13) is reported.

Section snippets

Acknowledgments

We thank Dr. Chuan-Yuan Li (Department of Radiation Oncology, University of Colorado Health Sciences Center) for the 4T1-ODD-Luc. This work was supported by grants from Duke University (J.H.), Duke Chemistry Undergraduate Summer Research Program (Y.P.), and National Institutes of Health (NIH PO1 CA42745 and NIH/NCI CA40355 to M.W.D; NIH R01GM61870-09 to W.Y.). H.K. gratefully acknowledges the Korea Research Foundation Grant funded by the Korean Government (MOEHRD) (KRF-2006-352-E00028) for a

References and notes (25)

P. Vaupel
Semin. Radiat. Oncol.
(2004)
D.M. Brizel et al.
Int. J. Radiat. Oncol. Biol. Phys.
(1997)
M. Hockel et al.
Cancer Res.
(1996)
D.M. Aebersold et al.
Cancer Res.
(2001)
A.L. Kung et al.
Nat. Med.
(2002)
X. Zhang et al.
Cancer Res.
(2004)
B.J. Moeller et al.
Cancer Cell
(2004)
B.J. Moeller et al.
Cancer Cell
(2005)
B.J. Moeller et al.
Int. J. Radiat. Oncol. Biol. Phys.
(2005)
R.J. Viola et al.
Am. J. Roentgenol.
(2008)
A.S. Tarnawski et al.
J. Mol. Med.
(2003)
G.R. Macpherson et al.
Cancer Biol. Ther.
(2004)
D.T. Dang et al.
Cancer Res.
(2006)
G.L. Wang et al.
Blood
(1993)
F. Li et al.
Mol. Cell
(2007)
G.L. Semenza
Nat. Rev. Cancer
(2003)

J.A. Bertout et al.

Nat. Rev. Cancer

(2008)

G.L. Wang et al.

Proc. Natl. Acad. Sci. U.S.A.

(1995)

Cited by (25)

Synthesis and evaluation of 3-(phenylethynyl)-1,1′-biphenyl-2-carboxylate derivatives as new HIF-1 inhibitors
2021, Bioorganic Chemistry
Citation Excerpt :
Apigenin promotes the degradation of HIF-1α through HSP90 inhibition [16]. Manassantin A exhibits the activity of downregulating HIF-1α protein expression (IC50 = 1 ~ 10 nM) and inhibiting VEGF secretion [29]. Berberine enhances proteolysis of HIF-1α by proteasome [30].
Selaginellins are a type of rare natural products from the genus Selaginella with unusual alkynyl phenol skeletons and extensive biological activities. Previous structural simplification of these natural compounds afforded a series of diaryl acetylene derivatives with hypoxia-inducible factor 1 (HIF-1) inhibitory activity. In this study, we synthesized thirty compounds by stepwise optimization using methyl 3-(4-methoxylphenyl ethynyl)-[4′-methoxyl-1,1′-biphenyl]-2-carboxylate (1a) as a lead compound and evaluated their HIF-1 inhibitory activity by dual luciferase reporter assay. Among them, compound 9i displayed the most potent HIF-1 inhibitory activity (IC₅₀ = 1.5 ± 0.03 μM) with relatively low cytotoxicity. Under hypoxia, compound 9i showed no effect on the accumulation of HIF-1α protein in western blot analysis, but could down-regulate the expression of VEGF mRNA, the downstream target gene of HIF-1 pathway. Cell-based activity assay demonstrated that compound 9i could inhibit the hypoxia-induced migration, invasion and proliferation of HeLa cells at the concentrations of 1 ~ 5 μM. In mouse breast cancer xenograft model, compound 9i exhibited obvious tumor growth inhibition and very low toxicity at a dose of 15 mg/kg. The results suggested that compound 9i would be a potential antitumor agent via HIF-1 pathway inhibition.
Structure-activity relationships study of neolamellarin A and its analogues as hypoxia inducible factor-1 (HIF-1) inhibitors
2019, Bioorganic and Medicinal Chemistry Letters
The novel marine pyrrole alkaloid neolamellarin A derived from sponge has been shown to inhibit hypoxia-induced HIF-1 activity. In this work, we designed and synthesized neolamellarin A and its series of derivatives by a convergent synthetic strategy. The HIF-1 inhibitory activity and cytotoxicity of these compounds were evaluated in Hela cells by dual-luciferase reporter gene assay and MTT assay, respectively. The results showed that neolamellarin A 1 (IC₅₀ = 10.8 ± 1.0 μM) and derivative 2b (IC₅₀ = 11.9 ± 3.6 μM) had the best HIF-1 inhibitory activity and low cytotoxicity. Our SAR research focused on the effects of key regions aliphatic carbon chain length, aromatic ring substituents and C-7 substituent on biological activity, providing a basis for the subsequent research on the development of novel pyrrole alkaloids as HIF-1 inhibitors and design of small molecule probes for target protein identification.
The Hypoxic Response and Aging
2016, Handbook of the Biology of Aging: Eighth Edition
Cells, tissues, and organisms need to adapt to varying oxygen availability in order to survive. As a consequence, most organisms have evolved a response to low-oxygen environments, dubbed the hypoxic response. In mammals and most multicellular eukaryotes, the primary transcription factors responsible for this response are the hypoxia-inducible factors. Activation of these hypoxia-inducible factors protects from the damage associated with low oxygen and leads to changes in metabolism, vasculature, and cell survival. Recent work also suggests that the hypoxic response pathway can play an important role in aging. This chapter discusses the role of the hypoxic response pathway in protecting cells and organisms from low oxygen and how this pathway can act to affect aging and disease. We will also discuss the interactions between the hypoxic response and other aging-related pathways and how these pathways fit into aging research as a whole.
The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness
2012, Biochimica et Biophysica Acta - Reviews on Cancer
Citation Excerpt :
The anti-inflammatory activity of manassantins is mediated by its inhibition of NF-κB transactivation activity [503]. Manassantin A and B have been considered as potent HIF inhibitors because manassantin A and B exert their inhibitory activity against the hypoxia-induced HIF-1α and VEGF expression at the concentration range of 1 nM to 1 μM, and a complete inhibition was observed at 100 nM in T47D human breast tumor cells [504,505]. However, the precise molecular mechanism has not been fully elucidated, suggesting further in-depth investigation especially in models with tumor hypoxic microenvironment.
Hypoxia is one of the fundamental biological phenomena that are intricately associated with the development and aggressiveness of a variety of solid tumors. Hypoxia-inducible factors (HIF) function as a master transcription factor, which regulates hypoxia responsive genes and has been recognized to play critical roles in tumor invasion, metastasis, and chemo-radiation resistance, and contributes to increased cell proliferation, survival, angiogenesis and metastasis. Therefore, tumor hypoxia with deregulated expression of HIF and its biological consequence lead to poor prognosis of patients diagnosed with solid tumors, resulting in higher mortality, suggesting that understanding of the molecular relationship of hypoxia with other cellular features of tumor aggressiveness would be invaluable for developing newer targeted therapy for solid tumors. It has been well recognized that cancer stem cells (CSCs) and epithelial-to-mesenchymal transition (EMT) phenotypic cells are associated with therapeutic resistance and contribute to aggressive tumor growth, invasion, metastasis and believed to be the cause of tumor recurrence. Interestingly, hypoxia and HIF signaling pathway are known to play an important role in the regulation and sustenance of CSCs and EMT phenotype. However, the molecular relationship between HIF signaling pathway with the biology of CSCs and EMT remains unclear although NF-κB, PI3K/Akt/mTOR, Notch, Wnt/β-catenin, and Hedgehog signaling pathways have been recognized as important regulators of CSCs and EMT. In this article, we will discuss the state of our knowledge on the role of HIF-hypoxia signaling pathway and its kinship with CSCs and EMT within the tumor microenvironment. We will also discuss the potential role of hypoxia-induced microRNAs (miRNAs) in tumor development and aggressiveness, and finally discuss the potential effects of nutraceuticals on the biology of CSCs and EMT in the context of tumor hypoxia.
Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors
2012, European Journal of Medicinal Chemistry
Citation Excerpt :
A variety of HIF-1 inhibitors also have been identified in cell-based screens from natural product libraries [95] and activity-guided fractionation using plants and marine organisms, including sodwanone and yardenone triterpenes from the marine sponge Axinella [96], manassantin B and 4-O-demethylmanassantin B from Saururus cernuus [97], laurenditerpenol, a new diterpene from the tropical marine alga Laurencia intricata [98], and the terpenoid tetrahydroidoquinoline alkaloids emetine, klugine, and isocephaeline [99]. In 2009, Hong and co-workers reported manassantin A (35) and analogs with modified tetrahydrofuran configurations as HIF-1 inhibitors [100]. The manassantin A showed downregulation of the HIF-1α expression (IC50 = 1–10 nM) and inhibition of the secretion of VEGF.
Tumor hypoxia has been recognized as a common feature of solid tumors and a negative prognostic factor for response to treatment and survival of cancer patients. The discovery of hypoxia-inducible factor-1 (HIF-1), a molecular determinant of responses to hypoxia in mammalian cells, has renewed enthusiasm for discovery and development of targeted therapies exploiting the hypoxic tumor microenvironment. HIF-1 activity in tumors depends on availability of the HIF-1α subunit, the levels of which increase under hypoxic conditions and through activation of oncogenes and/or inactivation of tumor suppressor genes. Increased HIF-1 has been correlated with increased angiogenesis, aggressive tumor growth, and poor patient prognosis, leading to current interest in HIF-1 as promising anticancer drug target. In spite of an ever increasing number of putative small molecule inhibitors of HIF-1, only a few are progressing through preclinical and early clinical development. In this review, we will discuss recent advances in discovery and development of small molecule inhibitors that target the HIF-1 pathway as potential anticancer agents.
Synthesis and evaluation of quinazolin-4-ones as hypoxia-inducible factor-1α inhibitors
2011, Bioorganic and Medicinal Chemistry Letters

View all citing articles on Scopus

View full text

Analysis of HIF-1 inhibition by manassantin A and analogues with modified tetrahydrofuran configurations

Abstract

Graphical abstract

Section snippets

Acknowledgments

Semin. Radiat. Oncol.

Int. J. Radiat. Oncol. Biol. Phys.

Cancer Res.

Cancer Res.

Nat. Med.

Cancer Res.

Cancer Cell

Cancer Cell

Int. J. Radiat. Oncol. Biol. Phys.

Am. J. Roentgenol.

J. Mol. Med.

Cancer Biol. Ther.

Cancer Res.

Blood

Mol. Cell

Nat. Rev. Cancer

Nat. Rev. Cancer

Proc. Natl. Acad. Sci. U.S.A.